FDA has cleared the way for an early clinical trial of a new, off‑the‑shelf cell therapy designed to tackle metastatic castration‑resistant prostate cancer, a late and difficult stage of the disease. The investigational product, referred to in regulatory filings as ADI‑212, is a gene‑edited, “armored” gamma delta CAR T cell therapy that targets prostate‑specific membrane […]
A new clinical study is testing a smarter way to give radiation after prostate surgery. The approach, called daily adaptive radiotherapy, uses artificial intelligence to adjust the treatment plan every day based on how the patient’s anatomy looks at that moment. Early results from the first 42 patients in the DART-PHASER trial suggest the method […]
Prostate cancer often becomes dangerous because the tumor cells can change their identity to escape treatment. At first, most prostate cancers are “luminal”: they depend on the androgen receptor (AR), a protein that acts like a growth switch turned on by male hormones. Drugs that block this receptor, such as enzalutamide, usually work well at […]
A new phase 2 trial is evaluating MRT-2359 in combination with apalutamide for patients with androgen receptor (AR) mutation-positive metastatic castration-resistant prostate cancer, an advanced disease that may become resistant to standard hormone-directed treatments. The first patient has been dosed in the MODeFIRe-1 study, which plans to enroll up to 25 patients. Participants must have […]
For decades, PSA has been the main biomarker used to monitor prostate cancer. It is inexpensive, accessible, and clinically familiar, but it does not always reflect what is happening inside metastatic tumors. PSA production is linked to androgen-receptor signaling, meaning that treatment-resistant or neuroendocrine-like tumor clones may continue to grow without producing a corresponding PSA […]
The investigational B7‑H3–targeting antibody–drug conjugate AK157D1, recently cleared for a Phase I trial in advanced solid tumors, is especially compelling from a prostate cancer perspective because B7‑H3 (CD276) is one of the most uniformly expressed and biologically aggressive surface targets across the full disease continuum, from hormone‑sensitive to castration‑resistant and neuroendocrine phenotypes. Unlike PSMA, which […]
A University of Michigan study suggests that combining two types of drugs could offer a new approach to treating advanced, treatment-resistant prostate cancer. The research focused on tumors that have changed their identity through a process called transdifferentiation. These tumors can become more aggressive and may no longer respond well to standard treatments that target […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Here we are again, with more news about the new weapons that are being developed. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. […]
Prostate cancer cells can outsmart hormone therapy by rewiring how they use nutrients, and a new preclinical study from Weill Cornell Medicine shows exactly how. Published in Nature Metabolism, the work reveals that tumors hijack the metabolism of two common amino acids, isoleucine and valine, to boost cholesterol production inside the tumor. That extra cholesterol […]
Long-term follow-up from a randomized phase 2 trial suggests that the DNA vaccine pTVG-HP (MVI-816) may significantly extend overall survival in men with PSA-recurrent, non-metastatic, castration-sensitive prostate cancer. The findings are particularly notable because the vaccine did not improve the study’s original primary endpoint of 2-year metastasis-free survival. The trial enrolled 99 men whose prostate […]